Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
  • A61F6/02—Contraceptive devices; Pessaries; Applicators therefor for use by males
  • A61F6/04—Condoms, sheaths or the like, e.g. combined with devices protecting against contagion
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Definitions

• the present invention relates to providing the ability to engage in sexual intercourse for males having difficulty developing or maintaining penile erection, while isolating the inner tissues of the sex partner from contact with the active pharmaceutical agents used to counteract male impotence.
• the active pharmaceutical agents may cause hemorrhaging in the female reproductive system.
• the present invention provides an impermeable peripheral boundary which physically isolates the active pharmaceutical agent away from the female reproductive system.
• the present invention eliminates the need for painful conventional subcutaneous injections of pharmaceutical agents to treat male impotence.
• vasodilators known for producing penile erection by injection are, individually or in combination, papaverine, phentola ine, and prostaglandin E-l. A combination of the three aforementioned vasodilators is preferred for medically injecting into the penis to produce erection.
• Vasodilators thus being known for clinically producing erections, there remains to be developed a system of delivery of an effective vasodilator, such as prostaglandin, without the need for a painful injection into the male user.
• a system of drug delivery which has become known is the use of transdermal patches to deliver pharmaceutical materials percutaneously. Such transdermal patches are known for assisting users to quit smoking, as with NICODERM® of Marion Merrell Dow Inc. of Kansas City, MO 64114 or HABITROL® of Basel Pharmaceuticals, Division of Ciba-Geigy Corp., Summit, New Jersey 07901.
• NICODERM® is a nicotine transdermal system in which the user attaches a medication-containing patch to the skin for varying time periods over several weeks. The patches comprising the system contain medication in varying doses.
• HABITROL® includes a patch having an adhesive layer attached to a patch having an imbedded pad soaked with a solution of nicotine.
• transdermal patches have advantages over oral administration of medications, in that the transdermal medication is not interfered with by gastric acids or enzymes, nor does the liver have the ability to interfere during the effective period of drug administration.
• Transdermal patches are generally layered structures, with the bottom-most, skin-facing layer comprised of an adhesive having microholes. Above this adhesive layer is a medication-containing layer, and a waterproof cover layer is generally provided.
• the adhesive serves to attach the patch to the skin and the medication in the central layer is provided to the skin through the microholes in the adhesive layer.
• the medication enters the bloodstream by percutaneous absorption, or, in common parlance, transdermal penetration.
• a further advantage of the patches is that, to an important extent, they reduce or eliminate user mistakes and forgetfulness.
• transdermal patches provide slow-release, measured medication over a period of time much longer than would be available if similar medication were taken orally.
• vasodilator Nowhere in the prior art has there been a combination of a vasodilator and a transdermal patch for providing male erections, wherein the vasodilator is administered through a selected patch which contains an edgewise peripheral impermeable boundary, or is isolated within the inside of a condom, to prevent direct contact of the vasodilator with the woman's female reproductive system.
• a selected patch which contains an edgewise peripheral impermeable boundary, or is isolated within the inside of a condom
• U.S. Patent no. 2,577,345 of McEwen discloses a prophylactic condom having a reinforced cap to prevent breakage of the condom at the tip of the condom.
• U.S. Patent no. 2,586,674 of Lonne discloses a prophylactic condom with reinforced annular extensions for structural integrity of the condom.
• U.S. Patent no. 3,136,417 of Clinch discloses a method of treating the surface of a condom with a lubrication oil deposited upon the surface of the condom.
• U.S. Patent no. 2,600,212 of Dal Borgo describes a method of applying a layer upon a surface with the application of heat.
• U.S. Patent no. 3,339,546 of Chem discloses a patch bandage in general.
• U.S. Patent no. 3,677,225 of Czirely describes a shortened condom which is adhesively attached to the skin.
• U.S. Patent no. 3,998,215 of Anderson discloses a hydrogel pad attachable to the skin for electro-stimulation treatment of injured body limbs.
• U.S. Patent nos. 4,274,420, reissue 31,454, 4,306,551 and 4,307,717 of Hymes disclose substrate pads for attaching to the skin as electrodes or bandages.
• U.S. Patent no. 4,354,494 of Hogin discloses a condom with an annular ring strap to hold the condom in place.
• U.S. Patent no. 4,475,910 of Conway describes a condom catheter having an adhesive to prevent leakage during urinary medical tests.
• U.S. Patent no. 4,638,790, also of Conway, describes a condom having an adhesive to maintain the condom in place.
• Patent no 4,415,548 of Reddy discloses a condom saturated with a spermacide solution.
• U.S. Patent no. 4,640,688 of Hauser describes a urinary catheter with a pressure adhesive.
• U.S. Patent no. 4,798,600 of Meadows discloses a condom with structural parts.
• U.S. Patent no. 4,869,723 of Harmon describes a condom with adhesive to hold the condom in place. Furthermore, U.S. Patent no. 5,137,032 also of Harmon discloses a condom with adhesives to hold the condom in place.
• U.S. Patent No. 5,137,032 of Harmon describes a condom having internally sprayed spermacide medicine, and auxiliary texturized portions to increase stimulation, but does not suggest the use of a transdermal patch within a condom, wherein the transdermal patch emits a vasodilator directly to the skin.
• U.S. Patent No. 4,829,991 of Boeck uses a vasodilator such as nitroglycerine coated onto the inner surface of a condom for producing a penile erection.
• the problems with Boeck which are solved by the present invention are (1) that nitroglycerine is generally not an effective vasodilator for producing a penile erection; and (2) a major danger in using the invention of Boeck is that indiscriminate coating of the inner condom surfaces with vasodilator creates a risk of unwanted exposure of the user's sex partner to the vasodilator - with potentially dangerous results for the sex partner.
• Boeck With Boeck, a female sex partner could be exposed to unwanted inadvertent percutaneous vasodilator absorption if the condom ruptures or comes off during sexual intercourse. In addition, if the male condom user of Boeck's invention is not careful in applying and removing the invention, inadvertent female exposure to the vasodilator could occur.
• Boeck's problem of contraindicated sex partner exposure to vasodilator is to provide a transdermal vasodilator patch for a male user with or without a condom.
• the patch of the present invention contains the vasodilator in a sealed system, permitting it only to come in contact with the skin of the male user for desired percutaneous transdermal absorption.
• neither in the prior art is there discussed the use of discreetly obscuring the view of a vasodilator patch for male erections, by secreting the patch within the condom, for example, or adhered behind the male scrotum, but in any case discretely out of view from a sex partner to avoid embarrassment to the male user.
• the adhesive can comprise any well known sticky surgical grade adhesive or other pressure sensitive adhesive known to the art, applied by any conventional means, for example as more particularly described in U.S. Patents 4,638,790 and 4,475,910.
• the present invention comprises embodiments used outside of a condom, and thus requiring no condom at all.
• the non- condom embodiments will be referred to simply as embodiments.
• Those embodiments used in combination with a condom, and thus requiring a condom will be referred to as condom-embodiments.
• the adhesive itself will not be termed a layer in and of itself. Rather, adhesives will be discussed in the present invention as being coated upon or applied to surfaces comprising the patch.
• the layers of the patch of the present invention will be described in detai1, however.
• the term 'inside' will be used to describe surfaces facing or closest to the skin of the user.
• the term 'outside' will describe those portions of the invention which are furthest from the skin of the user, or face away from the skin of the user.
• the outer layer of a 3-layer patch is the layer which, when the patch is in use adhered to the skin of the user, is disposed farthest from the skin of the user.
• each of these layers are not limited to a single layer.
• the outer layer may be an outer protective barrier layer to prevent abrasions or tearing of the patch> and this at least one outer layer may be covered by a further outer layer, such as a water repellent layer.
• 'barrier' layer will also be used in this invention to describe the at least one outer layers of the patch, since this at least one outer layer comprises an impermeable barrier sealing the vasodilator materials under it and within the confines of the patch.
• under as in 'under the barrier layer', is used to mean between the barrier layer and the skin of the user, and the term 'under' does not necessarily connote a vertical disposition as used in this context.
• each of the same aforedescribed at least one outer layers will have two surfaces - an outer surface and an inner surface.
• the inner surface of each of the outer layers is the surface of each of the outer layers which faces toward the skin of the user.
• non-condom-embodiments and the condom-embodiments are similar in several ways. They are constructed of suitably thin and flexible materials, so as to be able to bend and conform comfortably with the movement of the surface of the skin.
• the transdermal patches are constructed of one or more layers, so that each patch presents at least one edge to the skin of the user.
• the at least one edge results from the fact that the patch can have a round tabular shape, and thus would have at least one edge.
• the patch can have any tabular shape, such as a square, oblong or oval, in which case the patch could have more than one edge.
• the shape of the patch is not critical to the present invention.
• the at least one edge may be tapered, and the edges made smooth, so that the patch presents a surface to the skin of the user which is as smooth and frictionless as possible, thus preventing undesirable abrasion and friction from dislodging the patch adhered to the skin of the user.
• all the patches are provided with an adhesive on the inner, skin-facing surface.
• the adhesive may be a coating sprayed on, or may be a distinct substrate layer with a tacky surface on both sides.
• all the embodiments are provided with a releasable liner. "This protective liner is a film which is easily removed from the" inner surface of the patch "just prior to application on the skin.
• a release agent in the form of a thin coating is applied to paper, polymer coated paper, or polymer film, which provides structure to the liner. This release agent is necessary to prevent the" skin-facing adhesive "from sticking to its protective liner. Silicone and fluorocarbon-coated release liners are commonly used in transdermal systems for this reason" (Cleary) . As a means of consistently describing the features of the present invention, the release liner will not be termed a layer in and of itself, since it is removed prior to application of the present invention.
• All of the non-condom embodiments are constructed with at least one outer, stretchable, impermeable barrier layer composed of polyvinyl, polyethylene, polyester or aluminized polymer films and composite films, or any other suitable, impermeable, stretchable and flexible material.
• the at least one outer layer extends beyond the perimeter of the underlying layers, and has an adhesive material on the inner surface.
• the underlying layer or layers of the patch depending on the embodiment, thus comprise and occupy a central area within the perimeter of and under the outer layer.
• the at least one outer layer serves as a seal, as further described in detail.
• the inner surface of this at least one outer layer is coated with an impermeable adhesive which serves the dual function of anchoring the transdermal patch to the skin of the user and attaching underlying layers to the at least one outer barrier layer.
• an impermeable adhesive which serves the dual function of anchoring the transdermal patch to the skin of the user and attaching underlying layers to the at least one outer barrier layer.
• the adhesive must adhere aggressively and instantaneously with only very slight pressure.
• the adhesive can be any well known sticky surgical-grade adhesive, or other pressure sensitive adhesive known to the art, and applied by conventional means. Examples are described in U.S. Patents 4,638,790 and 4,475,910.
• the patch is designed to contain the vasodilator so as to seal it in and prevent its leakage or escape from the area of intended male user skin contact. It is desirable to prevent any and all contact of the vasodilator with the inner tissues of the sex partner.
• the patch while permitting intended male user skin contact with the vasodilator, is designed with an impermeable outer layer, or barrier layer, to prevent vasodilator escape through the upper surface of the patch, and with an impermeable adhesive to prevent unwanted leakage at or from the at least one edge of the patch as well.
• the patch provides means for sealing the vasodilator within the central portion of the patch away from the woman's vaginal tissues.
• the vasodilator is provided within a layered transdermal patch. Delivery of the vasodilator to the penis is accomplished through percutaneous absorption.
• the three layers comprise at least one outer barrier layer, as described above, at least one middle layer containing the vasodilator, and at least one inner layer.
• the vasodilator is stored and contained in the at least one middle layer of the transdermal patch, which functions as a vasodilator reservoir conventionally in the manner of transdermal medication patches to deliver the vasodilator to the skin surface when the patch is adhered to the skin of the user.
• the at least one middle layer contains the vasodilator in a suitable transdermal vehicle, which, as described in U.S. Patent 5,124,158 to Ruwart et al., may be a liquid, a cream, a gel or a paste, all of which are generally known in the art for transdermal use.
• Typical transdermal compounds which may be used in the present invention, are polyethylene glycol, propylene glycol, triacetin, propyl carbonate, ethanol and isopropyl myristate.
• the aforementioned typical transdermal compounds may be contained in a reservoir or alternately can be applied to porous or other materials suitable for preparing a transdermal patch, as Ruwart, 5,124,158 has described.
• the at least one inner layer of the multi-layered patch is typical of similar inner layers of some conventionally constructed layered patches.
• the at least one inner layer of a 3-layered first embodiment of the present invention comprises a means for dispensing the vasodilator through the skin of the male user, for example, such as a membrane made of plastic in the transdermal patch art, having microholes.
• the microholes in the membrane provide openings that limit the surface area of the middle, vasodilator-containing layer exposed to the skin of the user, thus regulating the amount of vasodilator available.
• At least one inner layer membrane materials are usually films made from non-woven, woven or foamed polymers, or from films made porous by various techniques, as described by Gary W. Cleary in Transdermal Drug Delivery. Cosmetics and Toiletries. Vol. 106, May 1991.
• the inner, skin-facing surfaces of the at least one inner layer membrane is coated with a second, comparatively weaker adhesive, which anchors the at least one inner layer to the skin of the user.
• the aforementioned adhesive is weaker compared to the strong barrier layer adhesive, which secures the entire transdermal patch system to the skin of the user.
• the comparatively weaker, membrane-anchoring adhesive is permeable to allow diffusion of the vasodilator through the comparatively weaker adhesive, so as to permit vasodilator to reach and make contact with the skin of the male user. If diffusion of the vasodilator through this comparatively weaker adhesive failed to occur, the vasodilator could not reach the skin of the user, since the vasodilator is contained in the at least one middle layer of the patch and as such is spaced apart from the skin of the user by the weaker adhesive, among other materials as herein described.
• Such adhesives as the aforedescribed comparatively weaker adhesive are known to provide adhesion of the transdermal patch system to the skin, and yet are easily removed without removing any skin or leaving a residue. Desirable characteristics for such a comparatively weaker adhesive material include the ability to adhere very aggressively to a backing material, e.g., the skin-facing inner surface of the aforedescribed microhole membrane while adhering to a lesser extent to skin.
• Pressure sensitive adhesives which provide a desirable, relatively weak skin adhesion are viscoelastic materials, which, in solvent-free form, remain permanently "tacky", and are described by Cleary in Transdermal Drug Delivery.
• the construction of the multi- layered transdermal patch provides for the stretchable at least one outer layer to completely cover and seal the at least one middle and inner layers.
• the vasodilator is contained within the patch and only the skin of the male user is permitted to come in contact with it.
• the transdermal patch system thus seals and prevents leakage of the vasodilator, and prevents inadvertent unwanted contact of the internal tissues of a female sex partner with the vasodilator.
• This covering and sealing function of the outer layer of the multi-layered patch is also provided by the at least one outer layers in a 2-layer embodiment of the present invention and a flexible solid embodiment, both of which will be described in detail.
• the vasodilator is provided within a two-layered transdermal patch.
• the two-layer form is similar to the three-layer form, except that, unlike the 3-layer patch, the 2-layered embodiment has no membrane with microholes to restrict the diffusion of medication to the skin.
• this second, 2- layered embodiment makes a larger amount of vasodilator available to the skin of the user more quickly, since there is no icrohole membrane to restrict and regulate dispensing of the vasodilator to the skin.
• the two-layer patch has an impermeable outer barrier layer in the same manner as the 3-layered embodiment.
• the 2-layered second embodiment is provided with an impermeable adhesive material coated on the inner surface, which faces and adheres to the skin of the user, and a smaller at least one inner layer containing the vasodilator material.
• the impermeable adhesive coated upon the inner surface of the at least one outer layer serves the dual function of securing the at least one inner layer with vasodilator to the outer layer and also fastening the at least one outer layer to the skin.
• the at least one inner layer, covered by the at least one outer layer when the patch is in use, is thus secured to the skin by means of the at least one outer barrier layer being adhered to the skin of the user and serving as a broad bandage providing adhesion, anchoring, covering and sealing.
• the vasodilator carried within a suitable transdermal vehicle, is stored and contained in the smaller, inner vasodilator-reservoir layer of the 2-layered transdermal patch.
• the inner surface of the drug-containing at least one inner layer is coated with a second, comparatively weaker adhesive which is comparatively more easily releasable, and which serves to attach the drug carrying at least one inner layer to the skin of the user.
• this second adhesive is permeable to permit transmission of the vasodilator from the reservoir layer through the permeable adhesive and thence into direct contact with the skin of the male user.
• the difference between the 2- layered and 3-layered embodiments is that on the 3-layered embodiment, as above described, the weaker, more releasable adhesive is coated upon the at least one inner surface of the inner layer, which comprises a membrane having microholes.
• the analogous weaker adhesive is coated upon the vasodilator-containing patch layer itself, since there is no membrane having microholes in the 2-layered embodiment.
• the at least one inner surface of the drug-containing inner layer is not coated with a permeable adhesive, so that the vasodilator drug layer itself directly contacts the skin of the user.
• the vasodilator is confined under the at least one outer, barrier layer, which acts as a seal and prevents vasodilator material from escaping the confines of the transdermal patch.
• the impermeable stronger adhesive anchoring the at least one outer barrier layer to the skin of the user further serves to seal the vasodilator and thus prevents vasodilator leakage laterally from around the sides and the at least one edge of the patch.
• the 2-layer patch functions conventionally in the manner of transdermal medication patches to deliver the vasodilator to the skin surface when the patch is adhered to the skin of the user.
• the patch itself is suitably thin and flexible, so as to be able to bend and conform comfortably with the movement of the surface of the skin, and the at least one edge of the multiple layers may be tapered so that the patch presents a surface to the skin of the user which is as smooth and frictionless as possible, thus preventing undesirable abrasion and friction from dislodging the patch adhered to the skin of the user.
• the vasodilator is provided in the form of a flexible solid patch.
• the flexible solid patch is constructed of an outer, impermeable barrier layer, and at least one inner layer containing the vasodilator material.
• the at least one outer layer extends beyond the perimeter of the at least one inner layer.
• the vasodilator material is mixed with a comparatively weak adhesive, and the vasodilator-weak adhesive mixture is spread in a thin, slightly moist layer in the center of the inner surface of the impermeable, at least one outer barrier layer.
• the vasodilator-weak adhesive mixture comprises a material which has a rubbery texture and is a flexible solid.
• the adhesive component of the flexible solid may be the same as described in the wart remover transdermal patch known by the trade name TRANS- VER-SAL « in which the flexible solid material is comprised of polyethylene glycol-300 USP, Karaya, propylene glycol USP, and quaternium 15.
• the aforedescribed flexible adhesive material is mixed with about 15% salicylic acid for application to the skin for wart removal.
• the at least one outer layer is provided with a coating of a relatively stronger adhesive on its inner surface, as described in detail in the first and second embodiments of the present invention.
• the stronger adhesive serves the dual function of holding the vasodilator-mild second adhesive mixture to the inner surface of the patch and fastening the patch to the skin.
• the third embodiment patch itself and the vasodilator material are suitably thin and flexible, so as to be able to bend and conform comfortably with the movement of the surface of the skin.
• the patch functions conventionally in the manner of transdermal medication patches to deliver the vasodilator to the skin surface when the patch is adhered to the skin of the user.
• the vasodilator-mild adhesive mixture comprises the flexible solid material of this third, flexible solid embodiment of the present invention.
• the mild adhesive of the flexible solid-vasodilator mixture allows the vasodilator to be released for percutaneous absorption through the skin of the male user.
• the flexible solid comprising the vasodilator and mild adhesive mixture is secured in contact with the skin of the user when this flexible solid embodiment is in use.
• the three-layer embodiment provides the greatest control over the rate of dispensing of the vasodilator to the skin of the user.
• Vasodilator dispensing can be controlled by controlling the permeability of the relatively more releasable milder adhesive coated on the microhole membrane inner surface, by controlling the thickness of the microhole membrane inner layer, and by varying the size, number and spacing of the microholes.
• the 3-layer embodiment is the preferred embodiment.
• Selective variation and control of the effectiveness of the patch itself may also be achieved by varying the absolute dose of the vasodilator contained in the patch of the present invention and also, separately, by selectively varying the nature of the vasodilator.
• individual vasodilator materials such as papaverine produce penile erections, and it is also known to synergistically combine vasodilators such as papaverine, phentolamine and prostaglandin to produce erection.
• the patch of the present invention will be provided in a variety of dosages, comprising a spectrum from small dose to large dose, with said doses to be determined by a treating physician and/or an individual male user.
• vasodilator drug choice and dosage for the present invention will be determined by the usual and well known variety of individual medical considerations in the case of each user.
• the present invention is thus provided in a variety of vasodilator drugs, and drug combinations, and also in a variety of dosage strengths, so as to meet the medical requirements of the widest possible spectrum of male users.
• the second embodiment with an absence of a microhole membrane, is a preferable alternative.
• This second embodiment may be utilized without an adhesive on the inner surface of the inner layer, thus placing no adhesive and no membrane between the skin' of the user and the vasodilator reservoir.
• Such a no- inner-adhesive variant of the second embodiment produces the fastest vasodilator delivery to the skin among all of the embodiments of the present invention.
• All three above described embodiments can be used by affixing to various parts of the user's body in the genital area, for instance either on the penis, at the base of the penis, or behind the scrotum.
• the patch of the present invention is manufactured with a conventional release liner material for protecting the adhesive.
• the release liner is removed by the user just before applying the patch to the skin.
• the user peels off the release liner from the adhesive of the presedt invention in the manner of release liner removal from well- known strip bandages.
• strip bandages light manual pressure will serve to cause adherence of the aforedescribed adhesives to the skin of the user.
• the patch When used at the base of the penis, the patch may be manufactured as a strip with rounded ends, placed circumferentially at the base of the penis substantially as an annular ring, or may be any other convenient shape.
• the patch may be manufactured as a plurality of small round or oval disks, and, if so, preferably as a pair of such disks. These disks are preferably placed at the base of the penis, one on each side, for example, where the plurality is comprised of a pair of such disks.
• the material and/or materials of the patch in all three embodiments may be made stretchable to accommodate the distention of the skin adjacent to the at least one inner layer during erection.
• the substrate of the at least one inner layer or layers may be made stretchable to accommodate the distention of the skin adjacent to the at least one inner layer during erection.
• the at least one outer layer may be manufactured of a stretchable plastic or latex. The patch or plurality of patches would be placed at the sides of the flaccid penis, near the base.
• the stretchable at least one outer layer expands to accommodate the increased circumference and length of the penis, without causing undue constriction or discomfort, and at the same time the at least one outer layer would continue to adhere firmly to the skin of the user.
• the patch has at least one edge, since it is wafer-like in contour, and may be manufactured as a disk, a square, or any useful shape for a medicinal patch.
• the patch may be provided with a taper in its thickness, so that while its thickness is not great, the thickness is nonetheless tapered toward the at least one edge.
• the at least one edge is further made smooth. The tapering and smoothness of the at least one edge ensures a substantial absence of friction and mechanical obstruction when the patch moves relative to an adjacent surface.
• the patch When used behind the scrotum, the patch may be manufactured as an oval, rounded triangle, or any useful shape for a medicinal patch. Hair in this scrotum area may need to be removed to allow effective contact between the patch and the skin of the user.
• the present invention also combines a conventional condom with a transdermal patch-delivered vasodilator pharmaceutical material for generating and maintaining the erection of the penis for sexual intercourse. Delivery of the vasodilator to the penis is accomplished essentially through percutaneous absorption.
• the condom-embodiments of the present invention it is necessary to place the transdermal patch near or substantially at the tip of the condom, where the condom tip may also be identified as the reservoir end, the sealed end, or the distal end for reference.
• the transdermal patch will be applied to the penis at, on or near the glans thereof, depending upon user application of the condom- transdermal patch combination.
• the patch When used by uncircumcised males, the patch may have to be located behind the foreskin of the user. Nonetheless, in the case of uncircumcised males, the in- condom patch will be disposed within the condom so as to result in placement at, substantially at, or near the glans of the user's penis.
• the present invention may be manufactured with a suitable marker on the outside of the condom to visually indicate the location of the patch. If concealment so as not to embarrass the male user is desired, the visual marker of patch location in the condom may be absent or dimly distinguished, so that the user may know its location without unduly calling attention visually to the fact that the condom has anything inside of it.
• Use of a visual marker is not critical to the present invention since the user will have to remove the releasable liner when applying the condom, so he will know where the patch is. In addition, the user will probably be able to feel the patch, even though the patch is stretchable. Also, unless the condom is totally opaque, the patch will be somewhat visible through the condom.
• the patches used in all of the condom-embodiments can have any tabular shape, such as a square, oblong or oval, or any other suitable shape.
• a preferable alternative to a disk, square or other shape of patch in any of the condom- embodiments is to construct the transdermal patch as an annular ring disposed within the condom, preferably disposed so as to be at, substantially at, or near the glans of the user's penis when the patch is in use.
• the shape of the patch is not critical to the present invention.
• the material and/or materials of the patch in all the condom-embodiments may be made stretchable to accommodate the distention of the skin adjacent to the patch during erection.
• the first three condom-embodiments of the present invention are similar to the three non-condom embodiments discussed above.
• Each of the above described non-condom embodiments is provided within a conventional condom.
• the vasodilator is provided within a three- layered transdermal patch which is similar to the first non-condom embodiment described above, except that the at least one outer surface of the barrier layer is provided with an adhesive which attaches the 3-layer patch to the inner wall of the condom.
• the second condom-embodiment of the present invention is similar to the two-layered transdermal patch of the second non-condom embodiment described above, except that the at least one outer surface of the barrier layer is provided with an adhesive which attaches the 2-layer patch to the inner wall of the condom.
• the vasodilator is provided within a flexible solid transdermal patch, except that the outer surface of the at least one barrier layer is provided with an adhesive which attaches the flexible solid patch to the inner wall of the condom.
• a 3- layered condom-embodiment is preferred because it gives the greatest control over the rate of dispensing of the medication, but, in cases where the rate of dispensing needs to be maximized, the second, 2-layered embodiment, without adhesive on the inner surface of the inner layer, is a preferable alternative.
• Each of the condom-embodiments described above can be constructed in two variations, each employing a different strength of the adhesive used to attach the patch to the inner wall of the condom. In the first variation, there is an adhesive system employing adhesives of different strengths for selective release.
• the adhesive securing the transdermal patch to the condom wall is made releasable, and thus weaker, whereas the adhesive securing the patch to the penis skin is made stronger.
• the condom wall adhesive releases, while the penis skin adhesive remains secured to the skin of the user's penis.
• the transdermal patch is thereby transferred from the condom wall to adhesive contact with the skin of the user's penis when the patch is put into use.
• This selective adhesive system herein described can be user controlled or can function automatically. Where user control is desired, the stronger penis skin adhesive upon the inner surface of the transdermal patch is made pressure sensitive. The user applies manual pressure upon the outside wall of the condom adjacent to the position of the transdermal patch which is inside the condom. The user will know the location of the patch because a suitable visual indicator is provided on the outside wall of the condom adjacent to the location of the patch.
• the weaker, releasable adhesive securing the patch to the condom wall will thereupon release, allowing the patch to remain on the penis and to move relative to the inside wall of the condom along with the penis.
• each patch in these various condom-embodiments is designed to prevent the vasodilator material from contacting the skin of the female during use.
• each patch is constructed with an impermeable barrier layer which comprises the at least one outer layer of each respective condom embodiment, and the adhesive that anchors the patch to the skin of the penis is designed to remain adhered to the skin of the penis, preventing any lateral leakage of the vasodilator.
• the adhesive anchoring the patch to the condom wall is not made releasable.
• the patch remains attached to the condom wall during use, and the adhesive which attaches the patch to the penis is not made stronger than the adhesive attaching the patch to the condom wall, so that the patch remains attached to both the inner condom wall and the skin during use, and removal of the condom from the penis will result in removal of the patch from penis skin contact as well.
• the adhesive which attaches the patch to the penis is not made stronger than the adhesive attaching the patch to the condom wall, so that the patch remains attached to both the inner condom wall and the skin during use, and removal of the condom from the penis will result in removal of the patch from penis skin contact as well.
• this is the preferred design of this embodiment.
• the surfaces which will be adjacent to the patch are (a) the condom wall; and (b) the skin of the penis.
• the transdermal patch is transferred from the condom wall to the skin of the user's penis by the system of differential adhesives described above. Therefore, in the first variation, the surface adjacent to the patch, relative to which the patch must move, is the inner wall of the condom.
• the above described thickness taper and smoothness of the at least one edge prevent mechanical tearing of the condom wall due to the relative motion of the patch and the condom wall.
• the patch remains attached to both of the adjacent surfaces.
• the further condom-embodiments of the present invention are similar to each other in that the transdermal patch has no at least one outer, impermeable barrier layer.
• the wall of the condom itself serves as the barrier, preventing leakage of the vasodilator.
• the patch must remain anchored to the inner wall of the condom, so that removal of the condom will result in removal of the patch containing vasodilator as well.
• the patch may be provided with a taper in its thickness, so that while its thickness is not great, the thickness is nonetheless tapered toward the at least one edge.
• the at least one edge is further made smooth. The tapering and smoothness of the at least one edge ensures a substantial absence of friction or chafing when the patch is in use.
• the patch itself and the vasodilator material are suitably thin and flexible, so as to be able to bend and conform comfortably with the movement of the surface of the skin.
• the vasodilator is provided within a two-layered transdermal patch.
• the at least one outer, condom-facing layer contains the vasodilator in a suitable transdermal vehicle, contained in a reservoir or alternately applied to porous or other materials suitable for preparing a transdermal patch, as previously described.
• the outer surface of the at least one outer layer is provided with a strong adhesive, which anchors the patch to the inner surface of the condom.
• the at least one inner, skin-facing layer is a plastic membrane with microholes as previously set forth.
• the at least one inner layer is held in contact with the skin of the user by a suitable adhesive in accordance with the foregoing discussion and the microholes permit regulated dispensing of the vasodilator from the at least one outer reservoir layer of the patch to the skin of the user.
• the two surfaces of the at least one inner membrane layer are coated with a comparatively weak adhesive as follows: the inner surface of the at least one inner membrane layer is anchored to the skin of the user; the outer surface of the at least one inner membrane layer is also adhered to the outer reservoir layer.
• the aforedescribed weak adhesive is permeable, to allow dispensing of the vasodilator to the skin by diffusion through and across the weak permeable adhesive, as heretofore described.
• the second further condom-embodiment of the present invention is analogous to the earlier described flexible solid embodiments.
• the vasodilator material is mixed with a mild adhesive, and the vasodilator-mild adhesive mixture is spread in a thin, slightly moist layer on the inner surface of the condom.
• the vasodilator-mild adhesive mixture comprises a material which is a flexible solid, as described in detail above.
• the inner surface of the condom which will contact the flexible solid is provided with a coating of a stronger adhesive on its inner surface.
• the stronger adhesive serves the function of adhesively holding the at least one flexible solid layer to the inner surface of the condom, so that removal of the condom will result in removal of the at least one flexible solid layer as well.
• the patch functions conventionally in the manner of transdermal medication patches to deliver the vasodilator to the skin surface when the patch is adhered to the skin of the user.
• any of the aforementioned various condom-embodiments may be provided with a suitable lubricant and/or spermacide, such as Nonoxynol-9, or any other suitable lubricant/spermacide.
• the lubricant/spermacide would coat the entire inner and outer surfaces of the condom.
• the lubricant/spermacide can be isolated from the vasodilator material and from the adhesive material on the inner, skin- facing surface of the patch by the releasing liner.
• Fig. 2 is an exploded view of the embodiment of Fig. 1, with adhesives shown.
• Fig. 3 is a perspective cut-away view of the embodiment shown in Fig. 1, installed on a patch of skin.
• Fig. 4 is a perspective view of a 2-layered embodiment of the present invention.
• Fig. 5 is an exploded view of the embodiment of Fig. 4, with adhesives shown.
• Fig. 6 shows a perspective view of the flexible solid embodiment of the present invention.
• Fig. 7 shows an exploded view of the flexible solid embodiment of Fig. 6, with adhesive shown.
• Fig. 8 is a perspective view of a prior art condom.
• Fig. 9 is a cut-away sectional view of a multi-layered condom-embodiment of the present invention.
• Fig. 10 is an exploded perspective view of the condo - embodiment as in Fig. 9.
• Fig. 11 is a cut-away, sectional view of the 2-layered condom-embodiment of the present invention.
• Fig. 12 is a cut-away, perspective view of the flexible solid condom-embodiment of the present invention.
• Fig. 13 is a cut-away, sectional view of another condom-embodiment of the present invention.
• Fig. 13A is an exploded view of the condom-embodiment of Fig. 13.
• Fig. 14 is a cut-away, sectional view of another condom-embodiment of the present invention.
• Fig. 15 shows a cut-away, perspective view of a condom having a transdermal patch in the form of an annular ring disposed near the tip or head end of the condom.
• Figure 1 shows a perspective view of a multi-layered transdermal patch 10, for example, such as shown with three distinct layers, (first embodiment of the present invention) , having at least one impermeable outer barrier layer 11 having an inner surface 101 facing the skin of the user when the patch is in use, and outer surface 102, facing away from the skin of the user.
• Inner surface 101 extends circumferentially and radially beyond the inner layers in the manner of a covering.
• the portion of inner surface 101 which extends circumferentially and/or radially beyond the inner layers is peripheral area 120.
• Peripheral area 120 is coated with an impermeable sealing adhesive 14 for adhering the patch to the skin and sealing in the vasodilator, and thereby preventing the vasodilator material from spreading beyond the confines of patch 10.
• Patch 10 is provided with at least one middle layer 12 in which is conventionally contained and stored a vasodilator material for transdermal application to the skin.
• At least one middle layer 12 may contain the vasodilator in such conventional arrangements as described in U.S. Patent No. 3,742,951 of Zaffaroni, U.S. Patent No. 4,675,009 of Hymes, U.S. Patent No. 4,638,043 of Szycher, U.S. Patent No. 5,244,677 of Kreckel or as discussed in Cleary, supra.
• At least one middle layer 12 is in contact with both at least one outer layer 11 and at least one inner layer 13.
• At least one inner layer 13 is constructed of a layer which contains a means for dispensing the vasodilator through the skin of the user, such as, for example a plastic film with microholes, such as described in Clark, "Patching Up Drug Deliveries", Newsweek, June 30, 1986, p. 69.
• At least one inner layer 13 has an inner skin- facing surface 103 which is provided with a permeable adhesive 15, which anchors the at least one inner layer 13 to the skin.
• At least one inner layer 13 is in contact with and anchored to at least one middle layer 12 by means of a coat of adhesive shown elsewhere in Fig. 2 of the drawings. Also demonstrated is the tapering 17 of the edges of the at least one outer layer 11, so that patch 10 produces substantially no friction or mechanical interference when the patch undergoes movement relative to an adjacent surface with which the patch may be in slidable contact during sexual intercourse.
• release liner 18 which covers the inner surface of patch 10, i.e. peripheral area 120 of inner surface 101, as well as inner surface 103 of at least one inner layer 13 so as to protect the respective adhesive- coated surfaces until the patch is to be used. Release liner 18 is shown partially peeled back.
• Figure 2 is an exploded perspective view of the multi- layered patch 10 of Figure 1, in reversed view. At least one inner layer 13 is anchored to at least one middle layer
• At least one middle layer 12 has an inner skin facing surface 105 and an outer surface 106 facing away from the skin.
• Inner layer 13 has an inner, skin facing surface 103 and an outer surface 104.
• Outer barrier layer 11 has an inner surface 101 and an outer surface 102. Inner surface 101 is anchored to middle layer 12 by means of an adhesive 14 shown elsewhere in Fig. 1 of the drawings. Also shown is releasable liner 18.
• Figure 3 is a perspective cut-away view of multi- layered patch 10 of Figure 1, adhered to the skin 150 of a user, showing outer surface 102 of at least one outer layer 11, demonstrating the contact of at least one outer layer 11 with the skin, showing peripheral area 120 of at least one outer layer 11 extending beyond at least one middle layer 12 and at least one inner layer 13, and showing the central location of at least one middle layer 12 and at least one inner layer 13.
• Figure 4 is a perspective view of 2-layered transdermal patch 20 (second embodiment) , having an at least one outer barrier layer 21 which has outer surface 202 and inner, skin-facing surface 201.
• Inner surface 201 further has peripheral area 220 which extends circumferentially and radially beyond at least one inner layer 22.
• Peripheral area 220 is coated with an impermeable sealing adhesive 23 for adhering inner layer 22 to outer layer 21, and adhering the patch to the skin and sealing in the vasodilator, and thereby preventing the vasodilator material from spreading beyond the confines of patch 20.
• Patch 20 is provided with an at least one inner layer 22 in which is contained and stored a vasodilator material for transdermal application to the skin.
• At least one inner layer 22 has inner skin-facing surface 203 which is provided with a coat of permeable adhesive 15. Also shown is the tapering 17 of the at least one edge of at least one outer layer 21, so that patch 20 produces substantially no friction or mechanical interference when the patch undergoes movement relative to an adjacent surface with which the patch may be in slidable contact during sexual intercourse. Also shown is release liner 18, which covers the inner surface of patch 20, protecting adhesive-coated surfaces 201 and 203 until the release liner 18 is removed before the patch is adhered to the skin of the user. Release liner 18 is shown partially peeled back. In a variant of this embodiment, permeable adhesive coating 15 may be omitted.
• FIG 5 is an exploded perspective view of the two- layered patch 20 of Figure 4, in reversed view.
• Patch 20 is provided with at least one outer impermeable layer 21, having an inner surface 201 and an outer surface 202.
• the inner surface 201 of at least one outer layer 21 is coated with an impermeable adhesive 23, as shown elsewhere in Fig. 4.
• Patch 20 is also provided with an inner layer 22, having an inner surface 203 and an outer surface 204. Also shown is the tapering 17 of the at least one edge of at least one inner layer 22, so that patch 20 produces substantially no friction or mechanical interference when the patch undergoes movement relative to an adjacent surface with which the patch may be in slidable contact during sexual intercourse.
• release liner 18 which covers the inner surface of patch 20, protecting adhesive-coated surfaces 201 and 203 until release liner 18 is removed before the patch is adhered to the skin of the user. Release liner 18 is shown partially peeled back.
• Figure 6 is a perspective view of the flexible solid embodiment of the present invention (third embodiment) .
• Flexible solid patch 30 is provided with at least one outer layer 31 having inner skin-facing surface 301 and outer surface 302 with an impermeable adhesive 33 on its inner surface.
• the adhesive coating 33 anchors the at least one outer layer 31 to the skin of the user and additionally anchors the at least one flexible solid layer 32, which comprises at least one inner layer 32, and is further comprised of a mixture of vasodilator and permeable adhesive, to the inner surface 301 of at least one outer layer 31.
• Inner at least one flexible solid layer 32 further has inner surface 303. At least one flexible solid layer 32 is adhered to inner surface 301 so as to be in contact with the skin of the user when the patch is in use.
• At least one flexible solid layer 32 allows inner surface 301, with peripheral area 320, coated with impermeable adhesive 330, to contact the skin of the user when the patch 30 is in use. Also shown is the tapering 17 of the at least one edge of at least one outer layer 31, so that the patch 30 produces substantially no friction or mechanical interference when the patch undergoes movement relative to an adjacent surface with which the patch may be in slidable contact during sexual intercourse. Also shown is release liner 18, which covers the inner surface of patch 30, protecting adhesive-coated surfaces 301 and 303 until the release liner 18 is removed before the patch is adhered to the skin of the user. Release liner 18 is shown partially peeled back.
• FIG. 7 is an exploded perspective view of the flexible solid patch 30 of Figure 6, in reversed view.
• Patch 30 is provided with at least one outer impermeable layer 31, having an inner surface 301 and an outer surface 302.
• the inner surface 301 of at least one outer layer 31 is coated with an impermeable adhesive 33, as shown elsewhere in Fig. 6.
• Patch 30 is also provided with inner layer 32, having an inner surface 303 and an outer surface 304. Also shown is the tapering 17 of the at least one edge of at least one inner layer 32, so that patch 30 produces substantially no friction or mechanical interference when the patch undergoes movement relative to an adjacent surface with which the patch may be in slidable contact during sexual intercourse.
• release liner 18 which covers the inner surface of patch 30, protecting surfaces 301 and 303 until the release liner 18 is removed before the patch is adhered to the skin of the user. Release liner 18 is shown partially peeled back.
• Figure 8 is a perspective view of a conventional condom, having an outside surface 40, an inside surface 41, an open end 42 and a closed end 43.
• Transdermal patch 10 includes three substrate layers including an at least one outer barrier layer 11, having a coating of adhesive on outer surface 102 for contact with and adhesive bonding to the inside surface 41 of the condom, and, as shown elsewhere in the drawings, an at least one middle layer 12 containing the vasodilator, and an at least one inner layer 13 constructed of a layer which contains a means for dispensing the vasodilator through the skin of the user, for example, a plastic film with microholes.
• Patch 10 is similar in construction to the multi-layered patch shown in Figures 1-3, except that the outer surface 102 of at least one outer barrier layer 11 has an adhesive coat 44 which attaches patch 10 to the inner surface 41 of the condom.
• At least one barrier layer 11 includes peripheral area 101, which extends beyond the perimeter of at least one inner layer 13 and at least one middle layer 12, which layers 12 and 13 are co-ter imus in respect to each other's outer perimeters.
• Patch 10 is provided with release liner 18, which is shown partially peeled back.
• Figure 10 additionally shows transdermal patch 10 attached to inside surface 41 of condom 40.
• Inner surface 103 of inner layer 13 is provided with a permeable adhesive 15.
• the portion of inner surface 101 of outer barrier layer 11, extending circumferentially and/or radially beyond the inner layers, is peripheral area 120. Also shown is the tapering 17 of the edges of outer layer 11, middle layer 12 and inner layer 13.
• the strength of the condom adhesive 44 coated upon outer surface 102 for contact with and adherence to condom inner surface 41 can be varied so that, selectively, in one variant patch 10 remains attached to the inner surface 41 of the condom during use, or in an alternate variant with a more releasable adhesive used upon surface 102, the patch 10 releases from the inner surface 41 of the condom during use, and this releasing of patch 10 permits the patch to move slidably relative to the inner surface of the condom.
• the at least one barrier layer 11 is coated with an impermeable adhesive on its inner surface 101 that attaches to the skin of the penis and holds at least two inner layers 12 and 13 to the barrier layer.
• FIG. 11 is a cross-sectional perspective view of 2- layered transdermal patch 20 (second condom embodiment) .
• Fig. 11 shows a 2-layered patch analogous to that shown in Fig. 4, except that the patch of Fig. 11, being a condom embodiment, is provided with an adhesive coated upon outer surface 202 for contact with and adherence to condom inner surface 41.
• the patch of Fig. 11 is similar to that of Fig.
• the strength of the condom adhesive coated upon outer surface 202 for contact with and adherence to condom inner surface 41 can be varied so that, selectively, in one variant patch 20 remains attached to the inner surface 41 of the condom during use, or in an alternate variant with a more releasable adhesive used upon surface 202, the patch 20 releases from the inner surface 41 of the condom during use, and this releasing of patch 20 permits the patch to move slidably relative to the inner surface of the condom.
• the at least one barrier layer 21 is coated with an impermeable adhesive on its inner surface 201 that attaches to the skin of the penis and holds at least one inner layer 22 to the barrier layer.
• patch 20 Whether or not patch 20 releases from the inner wall of the condom, patch 20 remains attached to the skin of the penis. Also shown is the tapering 17 of outer layer 21 and inner layer 22.
• FIG 12 is a cut-away perspective view of the flexible solid condom-embodiment of the present invention (third condom embodiment) .
• Flexible solid patch 30 is provided with an at least one inner layer 32 contacting the skin of the penis.
• An outer surface 302 of the at least one outer layer 31 is provided further with a coat of adhesive which contacts and adheres to the inner wall 41 of the condom and thereby anchors patch 30 to the inner wall of the condom.
• the strength of this adhesive coat upon outer surface 302 can be selected so as to provide two variants of condom patch 30. In one such variant patch 30 remains attached to the inner surface 41 of the condom during use, by virtue of having the adhesive coating upon surface 302 be a relatively strong adhesive.
• the adhesive coating upon surface 302 is made less strong, so that patch 30 releases from the inner surface 41 of the condom during use, and this releasing of patch 30 permits the patch to move slidably relative to the inner surface of the condom.
• the inner surface 301 of the at least one barrier layer 31 is provided with a coating 33 of an impermeable adhesive that attaches to the skin of the penis and also secures at least one inner layer 32 to the barrier layer.
• the impermeable adhesive coating 33 on surface 301 comprises a coat upon peripheral area 320, which forms the outer part of surface 301.
• At least one inner layer 32 is comprised of a permeable adhesive/vasodilator mixture, which comprises the flexible solid.
• the permeable adhesive component of the inner layer 32 serves to anchor the inner surface 303 of the flexible solid to the skin of the user.
• Patch 30 is provided with a tapering 17 of the at least one edge of the at least one outer layer 31 and the at least one inner layer 32, so that patch 30 produces substantially no friction or mechanical interference when the patch undergoes movement relative to an adjacent surface with which the patch may be in slidable contact during sexual intercourse.
• FIGS. 13 and 13A are two views of the fourth condom- embodiment of the present invention.
• Figure 13 is a cut ⁇ away perspective view of patch 50, which is adhesively attached to the inner surface 41 of the condom.
• Figure 13A is an exploded view of the patch of Fig. 13.
• Patch 50 is provided with an at least one outer layer 51 which contains the vasodilator, and an at least one inner layer 52, which comprises a plastic film having microholes for regulating dispensing of vasodilator to the skin of the user.
• At least one outer layer 52 has an outer surface 502 and an inner surface 501 (shown in Figure 13A) .
• At least one inner layer 52 has an outer surface 504 (shown in Fig. 13A) and an inner surface 503.
• the inner surface 501 of at least one outer layer 53 is coated with a permeable adhesive 53, which anchors the at least one inner layer 52 to the at least one outer layer 51.
• the inner surface 503 of at least one inner layer 52 is also coated with a permeable adhesive, which anchors the at least one inner layer 52 to the skin of the penis.
• Outer surface 502 of the at least one outer layer 51 is provided with an adhesive that anchors patch 50 to the inner surface 41 of the condom. Also shown is the tapering 17 of the edges of the layers, so that patch 50 produces substantially no mechanical interference during sexual intercourse.
• Releasable liner 18 covers the inner surface of at least one inner layer 52, and is shown fully removed.
• FIG 14 is a cut-away perspective view of the fifth condom-embodiment of the present invention, showing flexible solid transdermal patch 60 adhesively attached to the inner surface 41 of the condom.
• Patch 60 is provided with one layer 60 which is comprised of a permeable adhesive/vasodilator mixture, which constitutes the flexible solid.
• the permeable adhesive component of the flexible solid anchors the patch to the skin of the penis.
• the tapering 17 of the edges of the layers so that patch 60 produces substantially no mechanical interference during sexual intercourse.
• Releasable liner 18 covers the inner surface of at least one inner layer 60, and is shown fully removed.
• Figure 15 shows a perspective view of a condom 40 having a transdermal patch in the form of an annular ring 70 disposed near and/or substantially at the closed end of the condom. Also shown is the tapering of the edges 17 of patch 70. The area occupied by annular ring transdermal patch 70 includes substantially less than one half of condom inner surface 41. It is assumed that other modifications may be made to the present invention, without departing from the spirit and scope of the present invention, as noted in the appended claims.

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Dermatology (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Reproductive Health (AREA)
• Urology & Nephrology (AREA)
• Biomedical Technology (AREA)
• Vascular Medicine (AREA)
• Gynecology & Obstetrics (AREA)
• Heart & Thoracic Surgery (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Orthopedics, Nursing, And Contraception (AREA)

Applications Claiming Priority (5)

Publications (2)

Family

ID=26750627

Family Applications (1)

Country Status (5)

Families Citing this family (4)

Family Cites Families (7)

• 1994
  • 1994-05-20 CA CA002161974A patent/CA2161974A1/en not_active Abandoned
  • 1994-05-20 EP EP94918664A patent/EP0702540A4/de not_active Withdrawn
  • 1994-05-20 JP JP7500927A patent/JPH08510674A/ja active Pending
  • 1994-05-20 WO PCT/US1994/005875 patent/WO1994027536A1/en not_active Ceased
  • 1994-05-20 AU AU69887/94A patent/AU6988794A/en not_active Abandoned

Also Published As

Similar Documents

Legal Events